活動性強直性脊椎炎患者のチルドラキズマブの有効性と安全性: 無作為化二重盲検プラセボ対照フェーズ2a試験
J Clin Rheumatol. 2023;29(5):223–229 doi: 10.1097/RHU.0000000000001973
Phase 2a study assessing the efficacy and safety of tildrakizumab in patients with active AS fails to meet the primary endpoint.